Quarterly ResultMay 13, 2026, 04:19 PM
Eledon Tegoprubart Shows 100% Insulin Independence; Q1 Net Loss $39M
AI Summary
Eledon Pharmaceuticals reported its first quarter 2026 financial results and significant business highlights. The company announced that its investigational product, tegoprubart, achieved 100% insulin independence in 10 patients with type 1 diabetes following islet transplantation in an investigator-led study. Additionally, tegoprubart received FDA Orphan Drug designation for liver transplantation and showed positive 24-month data in kidney transplantation. Financially, Eledon reported a net loss of $39.0 million for Q1 2026, an increase from $6.5 million in Q1 2025, largely due to non-cash warrant liabilities, and holds $111.1 million in cash, expected to fund operations into Q2 2027.
Key Highlights
- Tegoprubart achieved 100% insulin independence in 10 type 1 diabetes patients post-transplant.
- FDA granted Orphan Drug designation to tegoprubart for liver transplantation.
- Q1 2026 net loss was $39.0 million, or $0.33 per basic common share.
- Research and development expenses increased to $17.2 million in Q1 2026 from $13.5 million YoY.
- Cash, cash equivalents, and short-term investments totaled $111.1 million as of March 31, 2026.
- Company expects current cash to fund operations into Q2 2027.
- 24-month Phase 1b kidney transplant data showed improved graft function and no acute rejection.